cyclophosphamide + epirubicin + nab-paclitaxel + pembrolizumab

A combination therapy regimen consisting of three chemotherapy agents (cyclophosphamide, epirubicin, and nab-paclitaxel) plus an immunotherapy agent (pembrolizumab). This regimen combines traditional cytotoxic chemotherapy with immune checkpoint inhibition. Pembrolizumab is a monoclonal antibody that blocks PD-1, enhancing T-cell immune responses against tumor cells. The chemotherapy components work through different mechanisms: cyclophosphamide is an alkylating agent that damages DNA, epirubicin is an anthracycline that intercalates with DNA and inhibits topoisomerase II, and nab-paclitaxel is a taxane that stabilizes microtubules and prevents cell division.